Glossary · healing peptide
BPC-157
Also known as: Body Protection Compound · Body Protective Compound 157 · BPC 157 · BPC157 · PL 14736 · Bepecin · BPC kosttilskudd
- Class
- healing peptide
- Half-life
- ~4 hours (est., subq)
- Typical dose
- 250–500 mcg/day
- Route
- subq / IM (local to injury preferred)
Mechanism
BPC-157 is a 15-amino-acid fragment derived from a gastric protective protein. It upregulates VEGFR2 signaling, driving angiogenesis at sites of soft-tissue injury, and modulates nitric oxide synthesis — the combination accelerates tendon, ligament, and gut mucosal repair. Unlike growth hormone pathway peptides, it works locally more than systemically, which is why injection proximal to the injury outperforms a single remote subq dose for orthopedic use.
It also has documented gut-protective effects (NSAID lesions, IBD-adjacent inflammation) and preserves vascular integrity under stress in animal models.
Typical protocol
- Starter: 250 mcg SC once daily, injected as close to the injury site as practical. Run 4 weeks on / 2 weeks off.
- Advanced: 500 mcg SC split AM/PM, local to the injury, for 4–6 weeks. Stack with TB-500 for tendon/ligament cases.
- Cycle length: avoid continuous use beyond 8 weeks. The tissue-healing window diminishes once the initial repair cascade resolves.
- Reconstitution: 2 mL bacteriostatic water into a 5 mg vial → 2.5 mg/mL. 10 IU on a U-100 insulin syringe = 250 mcg.
Who it's for
Recovery goal, hands down. Soft-tissue injuries (tendonitis, partial tears, post-surgical rehab), chronic joint issues, and gut-related inflammation. Not a muscle-building peptide, not a fat-loss peptide — don't force it into those roles.
Stacks well with
- tb 500 5mg — synergistic soft-tissue repair; BPC drives angiogenesis, TB-500 drives actin remodelling and cell migration.
- ghk cu 50mg — complementary collagen remodelling for dermal and joint matrix.
- beauty stack bpc tb500 ghk — pre-bundled BPC + TB-500 + GHK-Cu for combined recovery and connective-tissue work.
Watch-outs
- Will mask tendon and ligament pain. Keep training load honest or you'll re-injure once the signal is gone.
- Little evidence for acute fracture recovery — better for soft tissue than bone.
- Oral BPC exists in the literature but SC/IM is what actually works at these doses.
About BPC-157
What is BPC-157?
BPC-157 is a 15-amino-acid fragment derived from a gastric protective protein. It upregulates VEGFR2 signaling, driving angiogenesis at sites of soft-tissue injury, and modulates nitric oxide synthesis — the combination accelerates tendon, ligament, and gut mucosal repair.
What is the half-life of BPC-157?
Plasma half-life of BPC-157 is reported at ~4 hours (est., subq). This is a research-reference figure derived from published pharmacokinetic studies — administration timing and dosing intervals in published protocols are designed around this value.
What is the typical research dose range for BPC-157?
Published research-protocol ranges for BPC-157 fall between 250–500 mcg/day, administered subq / IM (local to injury preferred). These figures reference research-literature dosing only — they are not a clinical recommendation and BPC-157 is supplied here strictly as a research reagent.
What class of compound is BPC-157?
BPC-157 belongs to the healing peptide class of research peptides. It is also referred to in the literature as Body Protection Compound or Body Protective Compound 157. Each healing peptide compound shares overlapping pharmacology but differs in receptor selectivity, half-life, and reported research applications.
What is the typical research-protocol cycle for BPC-157?
Starter: 250 mcg SC once daily, injected as close to the injury site as practical. Run 4 weeks on / 2 weeks off.
BPC-157 research products
All products →
Glossary entries describe research pharmacology for in-vitro and laboratory contexts only.